Myriad Genetics Statistics Share Statistics Myriad Genetics has 93.04M
shares outstanding. The number of shares has increased by 1.49%
in one year.
Shares Outstanding 93.04M Shares Change (YoY) 1.49% Shares Change (QoQ) 0.95% Owned by Institutions (%) 99.99% Shares Floating 88.35M Failed to Deliver (FTD) Shares 41 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 9.37M, so 10.07% of the outstanding
shares have been sold short.
Short Interest 9.37M Short % of Shares Out 10.07% Short % of Float 14.16% Short Ratio (days to cover) 2.87
Valuation Ratios The PE ratio is -9.76 and the forward
PE ratio is 75.44.
Myriad Genetics's PEG ratio is
0.18.
PE Ratio -9.76 Forward PE 75.44 PS Ratio 1.48 Forward PS 0.7 PB Ratio 1.77 P/FCF Ratio -32.35 PEG Ratio 0.18
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Myriad Genetics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.82,
with a Debt / Equity ratio of 0.2.
Current Ratio 1.82 Quick Ratio 1.65 Debt / Equity 0.2 Debt / EBITDA -2.36 Debt / FCF -3.65 Interest Coverage -44.11
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $310.22K Profits Per Employee $-47.15K Employee Count 2,700 Asset Turnover 0.82 Inventory Turnover 9.17
Taxes Income Tax 3.8M Effective Tax Rate -3.08%
Stock Price Statistics The stock price has increased by -75.49% in the
last 52 weeks. The beta is 1.94, so Myriad Genetics's
price volatility has been higher than the market average.
Beta 1.94 52-Week Price Change -75.49% 50-Day Moving Average 5.39 200-Day Moving Average 9 Relative Strength Index (RSI) 64.59 Average Volume (20 Days) 1,733,835
Income Statement In the last 12 months, Myriad Genetics had revenue of 837.6M
and earned -127.3M
in profits. Earnings per share was -1.41.
Revenue 837.6M Gross Profit 585.4M Operating Income -123.5M Net Income -127.3M EBITDA -59.5M EBIT -120.7M Earnings Per Share (EPS) -1.41
Full Income Statement Balance Sheet The company has 102.4M in cash and 140.3M in
debt, giving a net cash position of -37.9M.
Cash & Cash Equivalents 102.4M Total Debt 140.3M Net Cash -37.9M Retained Earnings -756.8M Total Assets 677.3M Working Capital 84.4M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -8.7M
and capital expenditures -29.7M, giving a free cash flow of -38.4M.
Operating Cash Flow -8.7M Capital Expenditures -29.7M Free Cash Flow -38.4M FCF Per Share -0.42
Full Cash Flow Statement Margins Gross margin is 69.89%, with operating and profit margins of -14.74% and -15.2%.
Gross Margin 69.89% Operating Margin -14.74% Pretax Margin -14.74% Profit Margin -15.2% EBITDA Margin -7.1% EBIT Margin -14.74% FCF Margin -4.58%
Dividends & Yields MYGN does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for MYGN is $10,
which is 51.3% higher than the current price. The consensus rating is "Hold".
Price Target $10 Price Target Difference 51.3% Analyst Consensus Hold Analyst Count 12
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Mar 26, 2009. It was a
forward
split with a ratio of 2:1.
Last Split Date Mar 26, 2009 Split Type forward Split Ratio 2:1
Scores Altman Z-Score -1.78 Piotroski F-Score 4
